Biotechnology

Plandai Biotechnology, Inc. Announces Rescission of Material Definitive Agreement with Good Salt, LLC

August 1, 2023 3:15 PM

SAN DIEGO, CA / ACCESSWIRE / August 1, 2023 / Plandai Biotechnology, Inc. ("Plandai" or the "Company") (OTC:PLPL) announces today the rescission of a material definitive agreement with Good Salt, LLC due to the material failure of consideration in the transaction. The material definitive agreement, which was initially entered into on May 16, 2023, outlined the terms and conditions for the acquisition of the Company by Good Salt. However, despite...

Read more

iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology

August 1, 2023 8:00 AM

iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. MIAMI, FL & VILNIUS, LITHUANIA / ACCESSWIRE / August 1, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage regenerative medicine...

Read more

Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy

August 1, 2023 8:00 AM

Multi-year PCAOB audited financials completed Company on the path to become fully SEC reporting Future corporate action with name and symbol change MIAMI, FL / ACCESSWIRE / August 1, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical'' or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced that its auditors RBSM LLP have...

Read more

enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 31, 2023 4:45 PM

- Ended the quarter with $29.8 million in cash and investments with quarterly burn of $4.4 million - in line with Company guidance - Cash on hand sufficient to fund its current operations past the release of topline safety and efficacy data from the SAVVE® study and through the end of 2024 IRVINE, CA / ACCESSWIRE / July 31, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care...

Read more

AppYea Announces Appointment of Leading Medical Device Industry Executive Adi Shemer as CEO

July 31, 2023 9:30 AM

GAN YAVNE, ISRAEL / ACCESSWIRE / July 31, 2023 / AppYea Inc. (OTC:APYP), which is focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, today announced the appointment of Adi Shemer as Chief Executive Officer of the Company. Mr. Shemer has been working with the Company since February 2023 as a member of the advisory board. Mr. Shemer brings over 20 years of senior-level experience in revitalizing...

Read more

Imagene Welcomes World-Leading Oncologists at the Forefront of Precision Oncology to Its Scientific Advisory Board

July 31, 2023 8:00 AM

Visionaries and Experts, Each Having Played a Historical Role in Advancing Precision Oncology Into Current Clinical Practice TEL AVIV, ISRAEL / ACCESSWIRE / July 31, 2023 / Imagene, a pioneering leader in AI-based molecular profiling for precision oncology, is proud to announce the addition of distinguished members to its Scientific Advisory Board (SAB). The board comprises renowned oncologists and scientific medical leaders who are at the...

Read more

Biovica Signs US Commercial Agreement with Occum Health

July 31, 2023 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / July 31, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica today announces that the company has signed a commercial agreement with Occum Health for DiviTum® TKa in the US, making the blood test available to the more than 500 self-insured clients and key strategic partners. Occum Health is a healthcare solutions company focused on delivering savings and improved benefits to self-insured...

Read more

Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study

July 28, 2023 9:10 AM

KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp. ("LEXX Nutra"). The establishment of LEXX Nutra is in keeping with Lexaria's overall strategy of maximizing the potential for its patented DehydraTECH Technology in various...

Read more

Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients

July 27, 2023 6:00 PM

OMO-103 in Phase 1b clinical trial BARCELONA, SPAIN / ACCESSWIRE / July 27, 2023 / Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in...

Read more

SutimCo Inc. - New Business Acquisition

July 27, 2023 8:45 AM

DALLAS, TX / ACCESSWIRE / July 27, 2023 / SutimCo Inc. (OTC PINK:SUTI) ("SUTI") (the "Company") is excited to announce the acquisition of the Distribution Company; RJR Capital Partners LLC. The RJR Group specializes in new products developments and retail distribution for MJ based products and derivatives. The new, wholly-owned subsidiary, are bringing new and exciting brands, as well as supplying our strategic companies such as AURI, BDGR and...

Read more

NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform

July 27, 2023 8:30 AM

Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS Tumors Potential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology Market CLEVELAND, OH / ACCESSWIRE / July 27, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the signing of a Letter of Intent (LOI) and formation of a partnership with BCN...

Read more

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

July 26, 2023 9:00 AM

TORONTO, ON / ACCESSWIRE / July 26, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the Canaccord Genuity 43rd Annual Growth Conference being held in Boston from August 7-10, 2023. The Fireside Chat discussion between Edesa's Chief Executive Officer, Par...

Read more

Organicell Reports Interim Results of Phase 1/2A Research Program

July 26, 2023 8:30 AM

FORT LAUDERDALE, FL / ACCESSWIRE / July 26, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, today reported the results of its Phase 1/2A research program for its biologic therapeutic, ZofinTM, which contains high concentrations of nanoparticles, including exosomes, growth factors, and bio-active proteins. These...

Read more

Imagene's AI-Based Molecular Profiling Revolutionizes Lung Cancer Diagnostics: Two Patients Receive Immediate Targeted Therapy, Avert Brain Radiation

July 26, 2023 8:00 AM

A groundbreaking case report publication on the impact of rapid molecular testing on lung cancer patients TEL AVIV, ISRAEL / ACCESSWIRE / July 26, 2023 / Imagene, an emerging leader in AI-based precision oncology, is pleased to announce the publication of a case report in the Journal of Clinical Pathology. The report, titled "Artificial Intelligence (AI) Molecular Analysis Tool Assists in Rapid Treatment Decision in Lung Cancer'' demonstrates...

Read more

Albany Graphite Corp. Publishes Mineral Resource Estimate for Globally Unique Igneous Graphite Deposit

July 26, 2023 7:15 AM

GUELPH, ON / ACCESSWIRE / July 26, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, is pleased to announce an updated Mineral Resource estimate for the Albany Graphite Project located north of Lake Superior and southwest of James Bay in Northeastern Ontario, which is owned by Zentek's wholly-owned subsidiary Albany Graphite Corp. ("AGC"). Overview of the...

Read more

Early Announcement of Significantly Beneficial Clinical Trial Evidence From Young Blood Plasma Treatments

July 25, 2023 9:00 AM

Investigational young Fresh Frozen Plasma (yFFP®) Treatments Study YP042022 IRCM-2022-333 HOUSTON, TX / ACCESSWIRE / July 25, 2023 / Golden Gift, a 501(c)(3) nonprofit organization in support of the therapeutic use of blood plasma from young donors in treating age-related conditions, has shared an early announcement of significantly beneficial clinical trial evidence for Fresh Frozen Plasma (yFFP) Treatments. Chronic conditions developing in...

Read more

CORRECTION FROM SOURCE: Virogentics Announces Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRC

July 24, 2023 2:00 PM

Expects to Issue Update on EMA Progress ALLEN, TX / ACCESSWIRE / July 24, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). CORRECTED Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today it has received approval of the final protocol from the Department for HIV and AIDS, Ministry of Health of the DRC (Democratic Republic of the...

Read more

Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 and Diabetic Clinical Trials

July 24, 2023 8:55 AM

ALLEN, TX / ACCESSWIRE / July 24, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today it has received approval of the final protocol from the Department for HIV and AIDS, Ministry of Health of the DRC (Democratic Republic of the Congo). This paves the way for the projected August...

Read more

HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

July 24, 2023 7:30 AM

HanchorBio Received IND Approval of HCB101 Multi-Regional Clinical Trial By Taiwan FDA TAIPEI, TAIWAN and SAN FRANCISCO, CA / ACCESSWIRE / July 24, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its...

Read more

BioGX Candida Auris PCR Assay Global Adoption Accelerates

July 24, 2023 12:00 AM

BIRMINGHAM, AL / ACCESSWIRE / July 24, 2023 / BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities. A complete PCR mix is provided in a single lyophilized tube format to be validated by laboratories on a variety of...

Read more